RLAY
Bearish signalScored 2026-10-13 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Relay Therapeutics, Inc.
- Nom
- Relay Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $4.0B
- Employés
- 202
- PDG
- Sanjiv K. Patel
- Site web
- https://www.relaytx.com
- Marché
- AVBPERASIDYAKYMRNRIXORIC
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 96 398 titres (~1 785 290,96 $ US)
- Insiders
- Patel Sanjiv
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$3,789,250
Avg sell (VWAP, 90d window) $19.16 vs last close $16.28 (-15.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$3,706,547 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-07
- Liquidity
- Liquid $48,358,284/day · 20d vol
- Last synced
-
2026-10-17 09:40:48
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-07 | Patel Sanjiv | Sell · S · 10b5-1 | 48,199 | $18.10 | $872,402 | Form 4 |
| 2026-10-06 | Catinazzo Thomas | Sell · S · 10b5-1 | 206 | $19.26 | $3,968 | Form 4 |
| 2026-09-08 | Bergstrom Donald A | Sell · S · 10b5-1 | 8,530 | $18.97 | $161,814 | Form 4 |
| 2026-09-08 | Catinazzo Thomas | Sell · S · 10b5-1 | 17,717 | $18.94 | $335,560 | Form 4 |
| 2026-09-08 | Patel Sanjiv | Sell · S · 10b5-1 | 48,199 | $18.94 | $912,889 | Form 4 |
| 2026-08-26 | Rahmer Peter | Sell · S · 10b5-1 | 4,508 | $20.03 | $90,295 | Form 4 |
| 2026-08-17 | Patel Sanjiv | Sell · S · 10b5-1 | 48,199 | $20.33 | $979,886 | Form 4 |
| 2026-08-14 | Catinazzo Thomas | Sell · S · 10b5-1 | 17,717 | $19.74 | $349,734 | Form 4 |
| 2026-07-28 | Bergstrom Donald A | Sell · S | 2,237 | $18.61 | $41,631 | Form 4 |
| 2026-07-28 | Catinazzo Thomas | Sell · S | 1,459 | $18.61 | $27,152 | Form 4 |
| 2026-07-28 | Rahmer Peter | Sell · S | 748 | $18.61 | $13,920 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-07-12 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-13 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
RLAY presents a deeply unfavorable risk/reward profile: despite adequate liquidity (score 85), the fundamentals are severely deteriorating (score 35) with chronic negative margins, cash burn, and a shrinking headcount…
The first sentence of the analysis written for RLAY on 2026-10-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 22.61 · operating margin -1972% — readings disagree
Suggested stop 12.45, nearest stored support minus 0.5 ATR(23.6% under the last close). Reward/risk to the next stored resistance is 0.84. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 76.8% | -3052.2% | -1177.6% | -17496.3% | -5492.2% | |
| Ebit Margin | -1800.6% | -3854.0% | -1485.3% | -22516.4% | -7494.5% | |
| Ebitda Margin | -1777.4% | -3799.4% | -1464.6% | -22217.4% | -7364.9% | |
| Operating Profit Margin | -1971.6% | -3722.1% | -1460.1% | -21670.9% | -12040.2% | |
| Pretax Profit Margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | |
| Continuous Operations Profit Margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | |
| Net Profit Margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | |
| Bottom Line Profit Margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | |
| Current Ratio | 22.608 | 15.952 | 25.442 | 16.003 | 40.140 | |
| Quick Ratio | 22.608 | 15.952 | 25.442 | 15.812 | 40.140 | |
| Solvency Ratio | -5.029 | -3.553 | -3.661 | -1.915 | -3.253 | |
| Cash Ratio | 3.285 | 2.450 | 4.749 | 2.383 | 11.518 | |
| Price To Earnings Ratio | -5.255 | -1.746 | -3.946 | -5.768 | -8.039 | |
| Price To Earnings Growth Ratio | 0.165 | 0.113 | -0.511 | 0.179 | -0.163 | |
| Forward Price To Earnings Growth Ratio | 0.165 | 0.113 | -0.511 | 0.179 | -0.163 | |
| Price To Earnings Diluted Ratio | -5.255 | -1.746 | -3.946 | -5.768 | -8.039 | |
| Price To Earnings Diluted Growth Ratio | 0.165 | 0.113 | -0.511 | 0.179 | -0.163 | |
| Price To Book Ratio | 2.560 | 0.757 | 1.795 | 1.765 | 3.254 | |
| Price To Sales Ratio | 94.537 | 58.820 | 52.829 | 1,214.171 | 964.559 | |
| Price To Free Cash Flow Ratio | -6.154 | -2.344 | -4.433 | -7.029 | -37.516 | |
| Price To Operating Cash Flow Ratio | -6.165 | -2.363 | -4.494 | -7.307 | -39.266 | |
| Debt To Assets Ratio | 0.052 | 0.056 | 0.063 | 0.053 | 0.023 | |
| Debt To Equity Ratio | 0.057 | 0.062 | 0.071 | 0.061 | 0.026 | |
| Debt To Capital Ratio | 0.054 | 0.059 | 0.066 | 0.057 | 0.025 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.096 | 1.120 | 1.122 | 1.157 | 1.123 | |
| Working Capital Turnover Ratio | 0.023 | 0.013 | 0.030 | 0.001 | 0.004 | |
| Operating Cash Flow Ratio | -9.205 | -4.911 | -9.922 | -3.602 | -3.059 | |
| Operating Cash Flow Sales Ratio | -15.334 | -24.893 | -11.756 | -166.177 | -24.565 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.008 | 1.014 | 1.039 | 1.047 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -7.254 | -5.136 | -5.617 | -3.974 | -3.249 | |
| Capital Expenditure Coverage Ratio | -574.280 | -123.443 | -72.786 | -25.324 | -21.436 | |
| Dividend Paid And Capex Coverage Ratio | -574.280 | -123.443 | -72.786 | -25.324 | -21.436 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.130 | -1.349 | -3.366 | -5.158 | -11.944 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 76.8% | ▲3129.0% | ▲5505.1% |
| Ebit Margin | -1800.6% | ▲2053.5% | ▲5629.6% |
| Ebitda Margin | -1777.4% | ▲2022.0% | ▲5547.3% |
| Operating Profit Margin | -1971.6% | ▲1750.5% | ▲6201.4% |
| Pretax Profit Margin | -1800.6% | ▲1574.1% | ▲6112.0% |
| Continuous Operations Profit Margin | -1800.6% | ▲1574.1% | ▲6112.0% |
| Net Profit Margin | -1800.6% | ▲1574.1% | ▲6112.0% |
| Bottom Line Profit Margin | -1800.6% | ▲1574.1% | ▲6112.0% |
| Current Ratio | 22.608 | ▲6.657 | ▼-1.420 |
| Quick Ratio | 22.608 | ▲6.657 | ▼-1.382 |
| Solvency Ratio | -5.029 | ▼-1.476 | ▼-1.547 |
| Cash Ratio | 3.285 | ▲0.835 | ▼-1.592 |
| Price To Earnings Ratio | -5.255 | ▼-3.509 | ▼-0.304 |
| Price To Earnings Growth Ratio | 0.165 | ▲0.052 | ▲0.209 |
| Forward Price To Earnings Growth Ratio | 0.165 | ▲0.052 | ▲0.209 |
| Price To Earnings Diluted Ratio | -5.255 | ▼-3.509 | ▼-0.304 |
| Price To Earnings Diluted Growth Ratio | 0.165 | ▲0.052 | ▲0.209 |
| Price To Book Ratio | 2.560 | ▲1.803 | ▲0.534 |
| Price To Sales Ratio | 94.537 | ▲35.717 | ▼-382.446 |
| Price To Free Cash Flow Ratio | -6.154 | ▼-3.811 | ▲5.341 |
| Price To Operating Cash Flow Ratio | -6.165 | ▼-3.802 | ▲5.754 |
| Debt To Assets Ratio | 0.052 | ▼-0.003 | ▲0.003 |
| Debt To Equity Ratio | 0.057 | ▼-0.005 | ▲0.002 |
| Debt To Capital Ratio | 0.054 | ▼-0.005 | ▲0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.096 | ▼-0.025 | ▼-0.028 |
| Working Capital Turnover Ratio | 0.023 | ▲0.010 | ▲0.009 |
| Operating Cash Flow Ratio | -9.205 | ▼-4.295 | ▼-3.066 |
| Operating Cash Flow Sales Ratio | -15.334 | ▲9.559 | ▲33.211 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.006 | ▼-0.020 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -7.254 | ▼-2.118 | ▼-2.208 |
| Capital Expenditure Coverage Ratio | -574.280 | ▼-450.838 | ▼-410.827 |
| Dividend Paid And Capex Coverage Ratio | -574.280 | ▼-450.838 | ▼-410.827 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.130 | ▼-3.781 | ▲0.259 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.45B | $588.6M | $1.35B | $1.68B | $2.92B | |
| Enterprise value | $1.40B | $512.8M | $1.26B | $1.58B | $2.66B | |
| EV / Sales | 91.18x | 51.25x | 49.30x | 1146.07x | 879.64x | |
| EV / Op. cash flow | -5.95x | -2.06x | -4.19x | -6.90x | -35.81x | |
| EV / Free cash flow | -5.94x | -2.04x | -4.14x | -6.63x | -34.21x | |
| EV / EBITDA | -5.13x | -1.35x | -3.37x | -5.16x | -11.94x | |
| Net debt / EBITDA | 0.19x | 0.20x | 0.24x | 0.31x | 1.15x | |
| Current ratio | 22.61x | 15.95x | 25.44x | 16.00x | 40.14x | |
| Income quality | 0.85x | 0.74x | 0.88x | 0.79x | 0.20x | |
| Graham net-net | $3 | $5 | $5 | $8 | $9 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 87.6% | 90.1% | 93.4% | 160.3% | |
| Working capital | $552.7M | $758.5M | $739.8M | $955.8M | $951.9M | |
| Invested capital | $594.4M | $818.4M | $811.0M | $1.03B | $981.5M | |
| Return on assets | -44.5% | -38.8% | -40.5% | -26.4% | -36.1% | |
| Operating ROA | -40.6% | -43.4% | -38.4% | -28.4% | -40.3% | |
| Return on tangible assets | -44.5% | -38.9% | -40.6% | -26.5% | -36.2% | |
| Return on equity | -48.8% | -43.4% | -45.5% | -30.6% | -40.5% | |
| Return on invested capital | -50.5% | -45.1% | -45.6% | -28.8% | -37.0% | |
| Return on capital employed | -50.8% | -45.4% | -45.8% | -28.9% | -37.1% | |
| Earnings yield | -19.0% | -57.4% | -25.3% | -17.3% | -12.5% | |
| Free cash flow yield | -16.2% | -42.7% | -22.6% | -14.2% | -2.7% | |
| Capex / Op. cash flow | -0.2% | -0.8% | -1.4% | -3.9% | -4.7% | |
| Capex / Depreciation | 11.5% | 36.9% | 78.3% | 219.4% | 88.4% | |
| Capex / Sales | 2.7% | 20.2% | 16.2% | 656.2% | 114.6% | |
| SG&A / Sales | 369.3% | 801.8% | 307.6% | 5020.1% | 1972.5% | |
| R&D / Sales | 1702.3% | 3188.7% | 1291.9% | 17838.9% | 9760.6% | |
| Stock comp / Sales | 406.5% | 940.7% | 336.8% | 4065.0% | 1599.7% | |
| Intangibles / Total assets | 0.0% | 0.3% | 0.3% | 0.2% | 0.2% | |
| Days sales outstanding | 0d | 0d | 0d | 1379d | 595d | |
| Days payables outstanding | 791d | 16d | 10d | 16d | 18d | |
| Operating cycle | 0d | 0d | 0d | 1398d | 595d | |
| Cash conversion cycle | -791d | -16d | -10d | 1382d | 577d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-12 Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN) Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk. Analyst Recommendations This is a summary of recent
- 2026-10-11 Relay Therapeutics (NASDAQ:RLAY) CEO Sells $872,401.90 in Stock Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) CEO Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $18.10, for a total value of $872,401.90. Following the completion of the sale, the chief executive officer owned 471,301 shares of
- 2026-09-16 Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-16 Squarepoint Ops LLC Has $1.74 Million Position in Relay Therapeutics, Inc. $RLAY Squarepoint Ops LLC lessened its holdings in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 48.3% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 93,179 shares of the company''s stock after selling 87,119 shares during the quarter. Squarepoint Ops LLC''s holdings
- 2026-09-15 VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Stake in Relay Therapeutics, Inc. $RLAY VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 41,900 shares of the company''s stock, valued at approximately $784,000. A number of other
- 2026-09-10 Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
- 2026-09-10 Allianz Asset Management GmbH Makes New $750,000 Investment in Relay Therapeutics, Inc. $RLAY Allianz Asset Management GmbH acquired a new stake in Relay Therapeutics, Inc. (NASDAQ: RLAY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 40,100 shares of the company''s stock, valued at approximately $750,000. Other large investors have also recently made changes
- 2026-09-07 Frazier Life Sciences Management L.P. Takes $19 Million Position in Relay Therapeutics, Inc. $RLAY Frazier Life Sciences Management L.P. acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,015,693 shares of the company''s stock, valued at approximately $19,004,000. Frazier Life Sciences
- 2026-09-02 Relay Therapeutics CFO Sells 17,717 Shares for $350,000 The sale had an approximate value of nearly $350,000. The transaction reduced the executive''s direct equity position by 11%.
- 2026-09-01 Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September: